VeriMom¿Debo evitar naproxen durante el embarazo? | VeriMom
Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
ECHA regulatory hazard statements
- •H361
What to use instead
Pregnancy-safe ingredients that serve a similar function:
FAQ
- ¿Es naproxen seguro durante el embarazo?
- Systemic naproxen (an NSAID) is associated with fetal risks including oligohydramnios and premature closure of the ductus arteriosus; regulatory reviews and clinical guidance advise avoiding NSAIDs in pregnancy (especially after 20 weeks). Mechanistically this is via COX inhibition / reduced prostaglandins with demonstrated placental transfer. For topical cosmetic use, systemic exposure is expected to be low (low but measurable), so hazard is 'suspected' rather than confirmed. Sources: FDA/clinical review, peer‑reviewed reviews on NSAIDs in pregnancy, ECHA registration data.
- ¿Es naproxen seguro durante la lactancia?
- Naproxen is excreted into breast milk in low amounts but has a long half‑life and case reports of infant effects; professional guidance (LactMed, NHS Specialist Pharmacy Service, MotherToBaby) recommends caution and short‑term use if needed and consideration of alternative NSAIDs with shorter half‑lives. Mechanism is passive transfer into milk consistent with systemic exposure; expected exposure from topical cosmetic use is low but measurable.
- ¿Es naproxen seguro para la piel del bebé?
- No infant‑specific dermal teratogenicity data were found; systemic hazard stems from naproxen’s known reproductive effects. For baby (0–3 yr) skin, exposure scoring is increased by +1 due to immature barrier and higher surface‑area‑to‑weight, so exposure is moderate if a naproxen‑containing topical product were used repeatedly. There is no evidence to raise hazard or mechanism above the adult systemic evidence without infant‑specific studies.
- ¿Cómo puntúa VeriMom a naproxen?
- VeriMom puntúa naproxen en 20/100 (riesgo alto) según el estado EU CosIng, clasificaciones ECHA y estudios PubMed.
- ¿Cuáles son las alternativas seguras a naproxen en el embarazo?
- Consulta nuestra lista de alternativas seguras a naproxen según función similar y clasificación sin riesgos conocidos.
Comprueba cualquier etiqueta en 2 segundos
Descarga VeriMom gratis — escanea cualquier producto y ve la puntuación de seguridad en el embarazo al instante.
Aviso Médico
Esta información es solo para fines educativos y no constituye asesoramiento médico. Las puntuaciones de seguridad se basan en datos disponibles públicamente y pueden no reflejar todos los riesgos. Siempre consulte a su profesional de salud antes de usar cualquier producto durante el embarazo o la lactancia.